Polycystic kidney disease (PKD) is a genetic disease that affects the kidneys and other organs by causing uncontrolled growth of cysts in the kidney, eventually leading to kidney failure. Cysts are filled with fluid that grow inside the kidneys, causing them to become enlarged and interfere with their ability to filter waste products from the blood. PKD can cause chronic kidney disease, which could lead to kidney failure or end-stage renal disease. The two primary types of PKD are autosomal dominant PKD and autosomal recessive PKD. These two forms of PKDs are distinguished by the usual age of onset and the pattern in which it is passed through families. According to the PKD Foundation, autosomal dominant polycystic kidney disease affects more than 600,000 people in the U.S. and 12.4 million people globally. Autosomal recessive polycystic kidney disease is a rare form of the disease that occurs in 1 in 20,000 children across the world.

Get Report Details: https://www.transparencymarketresearch.com/polycystic-kidney-disease-treatment-market.html

The global polycystic kidney disease treatment market is projected to be propelled by technological advancements, leading to the development of a wide array of drugs, which will enable clinicians to provide better assistance to polycystic kidney disease patients. For instance, in July 2018, Reata Pharmaceuticals, Inc. announced positive phase II data for bardoxolone methyl for chronic kidney disease caused by alport syndrome and autosomal dominant polycystic kidney disease. PKD is prevalent in both developed and developing countries and affects all racial and ethnic groups equally. Government initiatives to spread awareness by implementing different programs about PKD is projected boost the growth of the global polycystic kidney disease treatment market. For instance, PKD Foundation invested over US$ 40 Mn in basic and clinical research grants for PKD diagnosis. However, less awareness in the underdeveloped countries and high cost associated with the treatment are likely to hamper the growth of the global polycystic kidney disease treatment market in the next few years.

Based on test type, the global polycystic kidney disease treatment market can be segmented into urine test, blood test, imaging test, and others. The blood test segment is projected to grow at a rapid pace during the forecast period, as doctors prefer a blood test to check for renal dysfunction in the initial stage of treatment. In terms of treatment, the market can be bifurcated into therapy and drugs. Presently, there is no cure for PKD. Treatment of the disease is focused on managing symptoms and complications. However, a new treatment is available that has shown to slow the progression of PKD to kidney failure. Most of the pipeline drugs for PKD are in the pre-clinical and discovery stage of development. The pipeline drugs for PKD consist of approximately 30 drug candidates in different stages of development.

Obtain the Report Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=54771

In terms of region, the global polycystic kidney disease treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017. The region is projected to account for significant share of the global polycystic kidney disease treatment market during the forecast period due to rise in prevalence and research on polycystic kidney disease treatment in the U.S. and favorable health care reimbursement policies. Extensive research and development on drug therapies to treat polycystic kidney disease by major players in countries such as Germany, Switzerland, and the U.K. is expected to drive the polycystic kidney disease treatment market in Europe. Significant growth of the medical and health care industry in China, Japan, and Australia is likely to propel the market in Asia Pacific in the near future. Advancements in tests and diagnosis, increase in per capita income, and availability of drugs are anticipated to augment the polycystic kidney disease treatment market in Middle East & Africa during the forecast period.

Players operating in the global polycystic kidney disease treatment market are Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., Celgene Corp, XORTX Pharma Corp, ManRos Therapeutics, Palladio Biosciences, Regulus Therapeutics, Inc., Kadmon Holdings, Inc., Reata Pharmaceuticals, Inc., NovaTarg Therapeutics, and Endocyte, among others. Increase in funding to these companies by government organizations contributes to the pipeline growth. For instance, in 2016, NovaTarg Therapeutics received US$ 3.2 Mn in SBIR grant funding. The company plans to progress its drug candidates for PKD and type 2 diabetes.

Opt for the Discount on the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=54771

About Us:

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com